​
Graph shows the average skin punch biopsy weight of mice treated topically with nitrogen mustard (NM) to induce skin inflammation. Mice additionally treated with polyamine-imidazole conjugates showed a marked decrease in skin inflammation. 
Invention Summary:
Non-steroidal Anti-Inflammatory drugs (NSAIDs) are widely available for over-the-counter use to reduce pain, inflammation and fever. However, traditional NSAIDs are often limited by short duration of action and lack of wound healing benefits. Developing a new class of NSAIDs that is more efficient, longer-lasting, and capable of actively promoting tissue repair presents a promising strategy for accelerating patient healing and improving clinical outcomes.
Rutgers researchers developed novel pharmaceutical compounds to treat inflammation and injuries in a variety of tissues. The new compounds conjugate a widely known NSAID with imidazole through a polyamine linker. A promising candidate combines indomethacin with imidazole through a diamine linker. The anti-inflammatory capability of this new compound was tested by observing inhibition of COX activity. Whereas currently available NSAIDs will inhibit COX-1 or COX-2 activity, the newly developed compound inhibited both COX-1 and COX-2. The improved anti-inflammatory activity of the NSAID-linked imidazole is a promising solution to improve NSAID potency and efficiency.
Market Applications:
- Treatment for inflammation, inflammatory diseases or injuries
- Accelerating wound healing
- Potential use in sports medicine, emergency medicine, dentistry, and post-surgery pain management
Advantages:
- Increased anti-inflammatory potency compared to currently available NSAIDs
- Potential wound healing benefits
Publications:
Intellectual Property & Development Status: Provisional application filed. Patent pending. Available for licensing and/or research collaboration. For any business development and other collaborative partnerships, contact: marketingbd@research.rutgers.edu
